We apologise for slow response on live chat as we are experiencing a sudden surge of more than 2000 queries per day! Please email to pr@thailandmedical.news for non-urgent queries. Thank You.

HIV / AIDs
Read all about the latests in HIV/Aids research and treatment protocols and also developments made into various specific components of managing this disease that is by itself also evolving.
Presented by
Source: La Jolla Institute for Immunology, California  May 11, 2019
A new HIV vaccine delivery strategy appears to enhance the protective immune response in a preclinical model. Scientists at the La Jolla Institute for Immunology (LJI) have discovered that delivering an HIV vaccine in small doses over a series of days leads to a stronger immune response than when the same vaccine is given all at once.   A similar escalating dose method could be the best way...
Source: NIH/National Institute of Allergy and Infectious Diseases,US  Apr 18, 2019
Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-42...
Source: The London School of Medicine (Blizard Institute)  Apr 05, 2019
A recent research found that long-term cotrimoxazole treatment reduces mortality and morbidity in children with HIV by altering their gut microbiome and immune activation. The finding supports current WHO guidelines, which recommend long-term cotrimoxazole treatment for all HIV-positive people living in areas where malaria and severe bacterial infections are common. Previous studies have shown...
Source: Conference on Retroviruses and Opportunistic Infections (CROI 2019) ,Seattle.  Mar 10, 2019
A combination of two long-acting injectable anti-HIV drugs taken once monthly had a very low rate of treatment failure and a favourable safety profile, according to results from two phase III trials presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle.    Dual injections of cabotegravir, an experimental integrase inhibitor, and the n...
Source: George Mason University   Feb 15, 2019
George Mason University's Yuntao Wu is the lead scientist on a research team that has identified a measurable indicator that could prove instrumental in the fight against HIV. The research focuses on cofilin, a key protein that regulates cells to mobilize and fight against infection. In an HIV-infected patient, cofilin dysfunction is a key factor in helper T cell defects, according to the ...